ArticleFrontiers in medicine2026
Changes in dermoscopic photoaging and serum MMP-1 following 12 weeks of 5% lady finger banana peel extract nanoparticle serum: a single-arm proof-of-concept study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lady finger banana peel ( Objective: To evaluate within-participant changes in facial photoaging manifestations and serum matrix metalloproteinase-1 (MMP-1) levels following 12 weeks of topical application of a 5% lady finger banana peel extract nanoparticle serum. Methods: This prospective, single-center, single-arm, uncontrolled pretest-posttest proof-of-concept study enrolled women aged 25-50 years with clinical signs of facial skin aging. Participants applied 10 drops, approximately 0.5 mL, of the study serum once nightly for 12 weeks. Serum MMP-1 levels were measured using enzyme-linked immunosorbent assay at baseline and week 12. Dermoscopy Photoaging Scale (DPAS) scores were evaluated at baseline and weeks 4, 8, and 12. Changes in serum MMP-1 levels and DPAS scores were analyzed using the Wilcoxon signed-rank test and Friedman test, respectively. Adherence and adverse events were evaluated throughout the study. Results: Fifty participants were enrolled, of whom one discontinued the study because of non-adherence. A total of 49 participants completed the study and were included in the analysis. Mean serum MMP-1 levels decreased from 0.48 ± 0.39 ng/mL at baseline to 0.26 ± 0.25 ng/mL at week 12 ( Conclusion: Lower DPAS scores and serum MMP-1 levels were observed following 12 weeks of topical serum use. Because this was an uncontrolled single-arm study, the findings should be regarded as preliminary and do not establish treatment efficacy, causality, systemic absorption, or modulation of cutaneous MMP-1. Randomized vehicle-controlled studies incorporating local skin biomarkers are required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.